UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.,
Petitioner

v.

NOVO NORDISK A/S,
PATENT OWNER

CASE IPR2024-00631
U.S. PATENT NO. 10,335,462
ISSUED: JULY 2, 2019

TITLE:
USE OF LONG-ACTING GLP-1 PEPTIDES

DECLARATION OF JUDITH KORNER, M.D., Ph.D.

March 1, 2024

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

Page

TABLE OF CONTENTS i

TABLE OF ABBREVIATIONS v

I. QUALIFICATIONS AND BACKGROUND 1

A. Education and Experience 1

B. Basis for Opinions and Materials Considered 4

C. Retention and Compensation 4

II. SUMMARY OF OPINIONS 5

III. LEGAL STANDARDS 7

IV. PERSON OF ORDINARY SKILL IN THE ART 8

V. THE '462 PATENT (Ex.1001) AND ITS CLAIMS 10

VI. CLAIM CONSTRUCTION 16

VII. BACKGROUND ON DIABETES AND THE USE OF GLP-1 DERIVATIVES FOR THE TREATMENT OF DIABETES 18

A. Diabetes Generally 18

B. Diabetes Treatment 20

C. The Use of GLP-1 Derivatives to Treat Diabetes 22

D. Use of Liraglutide to Treat Diabetes 24

E. Extended-Use GLP-1 Receptor Agonists 27

VIII. SCOPE AND CONTENT OF THE PRIOR ART 36

A. Lovshin (Ex.1012) 37

B. U.S. Patent Application Pub. No. US2007/0010424 (Ex.1016) 39

C. WO 2006/097537 (Ex.1015) 43

D. WO 2011/138421 (Ex.1011) 48

E. Semaglutide Clinical Trial Records 51

1. Clinical Trial No. NCT00696657 (Ex.1013) 51

2. Clinical Trial No. NCT00851773 (Ex.1014) 53

3. ClinicalTrials.gov is a Part of the POSA's Knowledge 55

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

F. Other Art that Informs the POSA's Knowledge 62
1. Drucker 2003 (Ex.1023) 62
2. Holst 2004 (Ex.1028) 63
3. Knudsen 2001 (Ex.1031) 66
4. Knudsen 2004 (Ex.1032) 70
5. Knudsen patent (U.S. Patent No. 6,268,343) (Ex.1034) 74
6. Lund (Ex.1035) 79
7. Victoza label (Ex.1039) 79
8. WO 03/002136 (Ex.1041) 82
9. Additional prior art and references 86

IX. UNPATENTABILITY OF THE CLAIMS OF THE '462 PATENT 87

A. Ground 1: WO421 Anticipated Claims 1-3 87
1. WO421 anticipated independent claim 1 87
2. WO421 anticipated claim 2 99
3. WO421 anticipated claim 3 101

B. Ground 2: Lovshin Anticipated Claims 1-3 103
1. Lovshin anticipated independent claim 1 103
a. Lovshin disclosed the preamble of claim 1 103
b. Lovshin disclosed the element "comprising administering semaglutide" 104
c. Lovshin disclosed the element "once weekly in an amount of 1.0 mg" 105
d. Lovshin disclosed the element "to a subject in need thereof" 108
2. Lovshin anticipated claim 2 109
3. Lovshin anticipated claim 3 110
4. Claim 1 of the '462 patent would have been obvious over WO421 alone 110

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

a. A skilled artisan would have been motivated to pursue the method recited in claim 1 111

b. A skilled artisan would have had a reasonable expectation of success treating type 2 diabetes with a once weekly, 1.0 mg dose of semaglutide 115

5. Claims 2 and 3 of the '462 patent would have been obvious over WO421 alone 118

6. Claims 4-10 of the '462 patent would have been obvious over WO421 in view of the '424 publication 121

C. Ground 4: Claims 1-10 of the '462 patent would have been obvious over WO537 in view of Lovshin 122

1. Claim 1 of the '462 patent would have been obvious over WO537 in view of Lovshin.....122

a. A skilled artisan would have been motivated to pursue the method recited in claim 1 122

b. A skilled artisan would have had a reasonable expectation of success treating type 2 diabetes with a once weekly, 1.0 mg dose of semaglutide 127

2. Claims 2 and 3 of the '462 patent would have been obvious over WO537 in view of Lovshin.....130

3. Claims 4-10 of the '462 patent would have been obvious over WO537 in view of Lovshin 132

D. Ground 5: Claims 1-10 of the '462 patent would have been obvious over NCT657 in view of NCT773 and further in view of the '424 publication 133

1. Claim 1 of the '462 patent would have been obvious over NCT657 in view of NCT773 133

a. A skilled artisan would have been motivated to pursue the method recited in claim 1 137

b. A skilled artisan would have had a reasonable expectation of success treating type 2 diabetes with a once weekly, 1.0 mg dose of semaglutide 143

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

2. Claims 2 and 3 of the '462 patent would have been obvious over NCT657 in view of NCT773 149

3. Claims 4-10 of the '462 patent would have been obvious over NCT657 in view of NCT773 and further in view of the '424 publication 151

E. No Secondary Considerations Overcome *Prima Facie* Obviousness.....152

1. No unexpected results 152

2. A POSA would have known there was no long-felt, unmet need for a once weekly GLP-1 receptor agonist or 1.0 mg dosing, nor was there any skepticism in the art.....153

X. RESERVATION OF RIGHTS.....153

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.